MedicalgorithmicsS.A.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-12-10
Share capital
1 045 338,90 PLN
Activity description

Medicalgorithmics is a Warsaw Stock Exchange-listed company developing technologies for cardiology. Its offering includes devices and platforms such as PocketECG, Kardiobeat.ai, AI & Software Platform, DeepRhythmAI (DRAI), DeepRhythm Platform (DRP), and Virtual Cardiac Stress Test (VCAST). The company also works in clinical trials, research and developments, and advanced diagnostics.

Registered address
al. Jerozolimskie 81, 02-001 Warszawa, Poland
Website
medicalgorithmics.comWebsite active
Electronic delivery address
AE:PL-16085-73484-VJTAG-35

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 25.20
+0.05 (+0.20%)
24.8025.0025.2025.4025.2010:0012:0014:0016:00
Open
PLN 25.15
High
PLN 25.35
Low
PLN 24.70
Volume
19.67K
Avg. vol.
12.42K
Market cap
PLN 250.81M
P/E ratio
—
EPS
-PLN 0.97
Shares outstanding
9.95M
52-week
PLN 24.70 – 26.05
Dividend yield
—
Dividend
—
Ex dividend date
—
ISIN
PLMDCLG00015
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q1 2026USD 2.76mUSD -100.76kUSD -580.23k
Q4 2025USD 2.52mUSD -88.90kUSD -235.31k
Q3 2025USD 1.81mUSD -846.31kUSD -1.02m
Q2 2025USD 1.75mUSD -494.22kUSD -626.07k

Results for Q3 2026:Nov 26, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 6.96mMedianUSD 72.15kAverageUSD 3.21m
Net profit
This companyUSD -2.64mMedianUSD 69.14AverageUSD 110.53k
Operating costs
This companyUSD 9.07mMedianUSD 75.02kAverageUSD 3.02m
Assets
This companyUSD 26.12mMedianUSD 121.49kAverageUSD 3.90m

News

Medicalgorithmics Advances AI Research Pipeline Targeting Automated Diagnostics and Population-Scale Cardiac Prevention

Medicalgorithmics Advances AI Research Pipeline Targeting Automated Diagnostics and Population-Scale Cardiac Prevention

Biofund is proceeding with its plans to convert the loan granted to Medicalgorithmics. The General Meeting will make a key decision

Biofund is proceeding with its plans to convert the loan granted to Medicalgorithmics. The General Meeting will make a key decision

Medicalgorithmics is entering a business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business

Medicalgorithmics is entering a business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business

Medicalgorithmics a technology partnership with Accyourate, an Italian wearable healthcare company

Medicalgorithmics a technology partnership with Accyourate, an Italian wearable healthcare company

Medicalgorithmics Summarizes the Q1 2025 51% revenue growth, positive EBITDA, and positive operating cash flow

Medicalgorithmics Summarizes the Q1 2025 51% revenue growth, positive EBITDA, and positive operating cash flow

Medicalgorithmics is entering the field of cardiac surgery robotics

Medicalgorithmics is entering the field of cardiac surgery robotics

Industry

Bank accounts

Registered as a VAT taxpayer on 2005-09-09. Active

  • mBank
    mBank
    15 1140 1010 0000 5495 5100 2003
  • mBank
    mBank
    42 1140 1010 0000 5495 5100 2002
  • mBank
    mBank
    69 1140 1010 0000 5495 5100 2001

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Jun 26, 2026Commercial Companies Code notice

Public aid

11 public aid cases recorded, with a total value of $4,383,519.

Grant datePurposeGross amountGranting body
Jul 21, 2026
De minimis aid (in accordance with Commission Regulation 2023/2831)
—PREZYDENT MIASTA GDAŃSK
Dec 17, 2025
Aid for research and development projects: experimental development
—Prezes Polskiej Agencji Rozwoju Przedsiębiorczości
Dec 17, 2025
Aid for research and development projects: experimental development
—Prezes Polskiej Agencji Rozwoju Przedsiębiorczości

European Funds

StartProjectEU co-financingProgramme
2026-01-01
101252780 - Af-b-step - quantifying atrial fibrillation burden to inform screening, treatment, and health policy
$0DA/JU/EUI - Decentralised Agencies, Joint Undertakings, EU institutions

Tenders

1 tender recorded as contractor, with a total value of $993,696.

Publication dateSubjectAmountContracting authority
Aug 26, 2025
Doposażenie w nowoczesny sprzęt i aparaturę medyczną ambulatoryjnej opieki specjalistycznej w SPZOZ w Działdowie
$993,696Samodzielny Publiczny Zakład Opieki Zdrowotnej w Działdowie

Regulatory authorisations

AuthorityTypeStatus
BDO
BDO register entry Active

Authorized Representatives

Krzysztof Borys Siemionow — President of the Management Board
Michał Zapora — Management Board Member

Manner of representation

In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Supervisory board

Paweł Bohdan Lewicki — Supervisory Board Member
Maksymilian Fraszka — Supervisory Board Member
Marcin Gołębicki — Supervisory Board Member
Michał Jerzy Żółtowski — Supervisory Board Member
Marzena Rozalia Piszczek — Supervisory Board Member

Beneficial owners

No beneficial owners recorded for the company Medicalgorithmics.

Subsidiaries

NameShare valueStake
Medicalgorithmics Polskasp. z o.o.
81,037.28 USD100%

Competitors

NameRevenueWebsite
ArdigenS.A.$12,513,309.89ardigen.com
Sidlysp. z o.o.$4,977,649.42sidly.eu
Scope FluidicsS.A.$4,660,220.99scopefluidics.com
MedappS.A.$3,351,163.61medapp.pl
BiotechnaS.A.$2,472,888.07bsbiotechna.com
Aurevia Polandsp. z o.o.$1,330,077.42aurevia.com
Saventic Healthsp. z o.o.$1,089,246.05saventic.com

Change history

DateEvent
2026-09-09Share capital change (995,276.90 PLN → 1,045,338.90 PLN)
2022-11-29Share capital change (497,638.50 PLN → 995,276.90 PLN)
2021-12-15Share capital change (432,782.90 PLN → 497,638.50 PLN)
2020-04-06Share capital change (360,652.60 PLN → 432,782.90 PLN)
2016-05-11Share capital change (345,552.60 PLN → 360,652.60 PLN)

FAQ

Last updated: 2026-09-09